ClinicalTrials.gg
CompletedNCT06072430VBI-S-02Updated Oct 26, 2026

A Phase III, Open Label, Randomized, Controlled Study of VBI-S in the Treatment of Hypovolemia in Patients With Septic Shock (VBI-S-02)

A Phase 3 interventional study of VBI-S in Septic Shock, Sepsis and Hypovolemia, sponsored by Vivacelle Bio. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Vivacelle Bio · Phase 3, Interventional, and Treatment

How we know

Updated Oct 26, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 164 studies in Shock, Septic with a site in United States — 18 open to participants now, 26 under way, 1 of them phase 3. Shock, Septic · United States.

Enrollment
67th of 116
39 · median 50
Started
2024
with 5 others
Phase 3
12 of 164
none open now
Registered
145th of 164
by date

Among the 164 studies in Shock, Septic with a site in United States, this one is the 67th largest by enrollment of the 116 interventional ones that give a count, is one of 6 that started in 2024, is one of 12 in phase 3, and was the 145th registered.

Shock, Septic

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

Browse Shock, Septic studies →

Open to participants now

18 of the 164 studies in Shock, Septic with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 164 studies in Shock, Septic with a site in United States, or all of them as a file.
02

Study summary

This study is being conducted to evaluate the safety and effectiveness of VBI-S in elevating the blood pressure of septic shock patients with absolute or relative hypovolemia.

Read the detailed description

PURPOSE OF THE STUDY This study is being conducted to evaluate the safety and effectiveness of VBI-S in elevating the blood pressure of septic shock patients with absolute or relative hypovolemia.

STUDY TREATMENT Sepsis is a serious condition resulting from the presence of harmful microorganisms in the blood or other tissues and the body's response to their presence, leading to the malfunctioning of various organs. When hypotension due to sepsis cannot be reversed with the infusion of fluids the patient is in a state of septic shock. Septic shock is therefore an acute medical emergency and delayed therapy can lead to organ injury. VBI-S is intended to raise blood pressure in patients with septic shock.

Randomization and blinding: This is a randomized, controlled, open-label study and blinding is not applicable to this study.

Data Safety Monitoring Board: A Data Safety Monitoring Board (DSMB) will review the study data.

03

Conditions studied

  • Septic Shock
  • Sepsis
  • Hypovolemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female at least 18 years of age.
  2. Evidence of bacterial infection demonstrated by positive blood culture and/or a known source of infection and/or an elevated procalcitonin of ≥ 2 ng/ml.
  3. Patient has a mean blood pressure \< 65 mmHg that is unresponsive to fluids currently available on the market.
  4. Sequential Organ Failure Assessment (SOFA) score ≥ 5
  5. Sepsis diagnosis: The presence of infection which can be proven or suspected by 2 or more of the following criteria:

    • Lactate > 2 mmol/L
    • Fever > 38.3°C, or 101°F
    • Hypothermia \< 36°C core temperature (\<96.8°F)
    • Heart rate > 90
    • Tachypnea (respiratory rate ≥ 20/min)
    • White blood cell count >12,000 or less than 4,000, or with >10% "bands" (immature forms)
    • Elevated procalcitonin in serum (≥ 2ng/ml)
    • Arterial hypoxemia (PaO2/FiO2 \< 300)
    • Creatinine increase > 0.5 mg/dL since hospital admission
    • > 1.5 or aPTT > 60 seconds
  6. Documented dysregulated host response to an infection as indicated by an increase in SOFA score by ≥ 2 points after an infection per the SEPSIS 3 guideline.
  7. Receiving vasopressors to maintain the target MAP of 65 mmHg.

Exclusion criteria

Exclusion Criteria:

  1. Patients with a ventricular assist device
  2. Acute coronary syndrome
  3. Pregnant
  4. Acute bronchospasm
  5. Acute Mesenteric ischemia
  6. Emergency major surgery
  7. Diagnosis of acute or C.
  8. Hematologic or coagulation disorders including thrombocytopenia ( count \<50,000) and associated with hemodynamically significant active bleeding that causes a decrease in blood pressure.
  9. White blood cell count of \< 1000 mm3
  10. Current participation or participation in another experimental or device study within the last 30 days before the start of this study. Patient may be included if on other drugs are for COVID-19.
  11. Patients with a known allergy to soybeans or eggs
  12. Patient is hypervolemic with assessment by physician or physician extender ultrasound 12 hours before infusion of VBI-S if hypervolemia is suspected.
  13. Patient expected to expire within 12 hours.
  14. Patients with disturbances in normal fat metabolism such as pathologic hyperlipemia, lipid nephrosis, or acute pancreatitis with hyperlipidemia.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    VBI-S

    Treatment with VBI-S

    Drug: VBI-S

Interventions

  • DrugVBI-S

    VBI-S is made of small particles of specific lipids called micelles and liposomes for the treatment of hypotension.

06

What researchers measure

Primary outcomes

  1. Elevation in Average Mean Arterial Pressure

    The primary endpoint is defined as an elevation in average mean arterial pressure by at least 10 mmHg from baseline within 3 hours of initiation of study treatment on Day 1

    Time frame: 12 months

Secondary outcomes

  1. Dose of Pressor Drugs

    The number of patients in whom the dose of pressor drugs could be decreased after infusion of VBI-S to maintain a mean arterial pressure of 60-65 mmHg.

    Time frame: 12 months

  2. Sequential Organ Failure Assessment (SOFA) Score

    Change in Sequential Organ Failure Assessment (SOFA) Score on a scale of 0 to 24. A higher score indicates a worse outcome.

    Time frame: 12 months

  3. Ratio of Arterial Partial Pressure of Oxygen/Fraction of Inspired Oxygen

    Change in ratio of partial pressure of oxygen in arterial blood/Fraction of inspired oxygen (P/F ratio).

    Time frame: 12 months

  4. Arterial Oxygen Saturation

    Change in arterial oxygen saturation.

    Time frame: 12 months

  5. Partial Pressure of Oxygen

    Change in partial pressure of oxygen.

    Time frame: 12 months

  6. Serum Procalcitonin

    Change in serum procalcitonin

    Time frame: 12 months

  7. Serum Creatinine

    Change serum creatinine

    Time frame: 12 months

  8. Post-treatment Survival

    Change in post-treatment survival

    Time frame: 12 months

Other outcomes

  1. Adverse Drug Reactions

    The number and proportion (%) of patients with treatment-emergent adverse drug reactions.

    Time frame: 12 months

07

Study locations

5 sites
  • Dignity Health Chandler Regional Medical Center
    Chandler, Arizona 85224, United States
  • Memorial Health University Medical Center
    Savannah, Georgia 31404, United States
  • University Health
    Kansas City, Missouri 64108, United States
  • Novant Healthcare
    Winston-Salem, North Carolina 27103, United States
  • Oregon Health & Science University (OHSU)
    Portland, Oregon 97239, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Jun 2026, 22 months.

Of 46 phase 3 interventional studies under Shock, Septic, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 59. This study's 22 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Dec 2025 → Jun 2026 and completion Dec 2025 → Jun 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2023
First posted
Oct 10, 2023
StartActual
Aug 6, 2024
Primary completionActual
Jun 29, 2026was Dec 2025
CompletionActual
Jun 29, 2026was Dec 2025
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 26, 2026
Sites
1 site removed
Show 1 removed
  • Bryan Medical Center · Lincoln, United States
Oct 26, 2026
Primary completion
Dec 2025→Jun 29, 2026 (actual)
Oct 26, 2026
Study completion
Dec 2025→Jun 29, 2026 (actual)
Oct 26, 2026
Enrollment
46 (estimated)→39 (actual)
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Recruiting→Completed
    1 site removed
    Show 1 removed
    • Bryan Medical Center · Lincoln, United States
    Primary completion Dec 2025→Jun 29, 2026 (now actual)
    Study completion Dec 2025→Jun 29, 2026 (now actual)
    Enrollment 46 (estimated)→39 (actual)
    + 4 other changes: registry dates, oversight details, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06072430
Lead sponsor
Vivacelle Bio
Responsible party
Sponsor
First posted
Oct 10, 2023
Start date
Aug 6, 2024
Primary completion
Jun 29, 2026
Completion
Jun 29, 2026
Last update
Oct 26, 2026

Study contacts

Cuthbert O Simpkins, MD, FACS
principal investigator · Vivacelle Bio

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion